Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix

被引:102
作者
Boruta, DM
Schorge, JO
Duska, LA
Crum, CP
Castrillon, DH
Sheets, EE
机构
[1] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA
关键词
D O I
10.1006/gyno.2000.6118
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Patients with early-stage neuroendocrine cervical carcinoma (NECC) have a high mortality rate despite aggressive therapy. The rarity of this tumor precludes initiation of a randomized, prospective trial. We reviewed our experience in early stage disease and performed a meta-analysis of the literature to identify prognostic factors and determine optimal multimodality therapy. Methods. Eleven women with International Federation of Gynecology and Obstetrics (FIGO) early stage (IB-IIA) NECC were treated with surgery and chemotherapy at our institutions between 1978 and 1998, Administration of radiation therapy was recorded, but not required for inclusion in this study. A gynecologic pathologist reviewed all histopathologic sections. Medical records were retrospectively reviewed and clinical data obtained. Twenty-three early-stage NECC patients who were similarly treated during the study interval were identified by a Medline search of the English literature and included in the analysis. The Kaplan-Meier method and log-rank test were used for survival analysis. Results. The overall 2-year survival rate for the 34 patients was 38%. The median age was 37 years (range, 20-75 years). Median cervical tumor diameter was 3.2 cm (range 0.5-11.0 cm), Lymphovascular space invasion was present in 21 (78%) of 27 patients (7 unknown). Fifteen (52%) of twenty-nine had lymph node metastases (5 unknown). Fifteen patients received postoperative platinum/etoposide (PE), seven received vincristine/adriamycin/cyclophosphamide (VAC), two received alternating cycles of VAC and PE, and ten received other chemotherapy regimens. Twenty women were treated with radiation therapy. The presence of lymph node metastases was a poor prognostic factor (P < 0.001), PE and VAC chemotherapy was associated with increased survival (P < 0.01). Conclusion. NECC is a highly lethal variant of cervical cancer. The presence of lymph node metastases is the most important prognostic variable. Postoperative VAC or PE appears most likely to improve chances for survival, (C) 2001 Academic Press.
引用
收藏
页码:82 / 87
页数:6
相关论文
共 27 条
[1]   ADJUVANT CHEMOTHERAPY IN STAGE IB NEUROENDOCRINE SMALL-CELL CARCINOMA OF THE CERVIX [J].
ABULAFIA, O ;
SHERER, DM .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1995, 74 (09) :740-744
[2]  
AlboresSaavedra J, 1997, ARCH PATHOL LAB MED, V121, P34
[3]  
BUNN PA, 1989, LUNG CANCER, V5, P127
[4]  
CHANG DHC, 1994, J REPROD MED, V39, P537
[5]  
Chang TC, 1998, CANCER, V83, P712, DOI 10.1002/(SICI)1097-0142(19980815)83:4<712::AID-CNCR12>3.0.CO
[6]  
2-V
[7]   RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND VINCRISTINE VERSUS CISPLATIN AND ETOPOSIDE VERSUS ALTERNATION OF THESE REGIMENS IN SMALL-CELL LUNG-CANCER [J].
FUKUOKA, M ;
FURUSE, K ;
SAIJO, N ;
NISHIWAKI, Y ;
IKEGAMI, H ;
TAMURA, T ;
SHIMOYAMA, M ;
SUEMASU, K .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (12) :855-861
[8]   SMALL-CELL UNDIFFERENTIATED CARCINOMA OF THE CERVIX - A CLINICOPATHOLOGIC, ULTRASTRUCTURAL, AND IMMUNOCYTOCHEMICAL STUDY OF 15 CASES [J].
GERSELL, DJ ;
MAZOUJIAN, G ;
MUTCH, DG ;
RUDLOFF, MA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1988, 12 (09) :684-698
[9]   SMALL-CELL CARCINOMA OF THE CERVIX TREATED WITH CONCURRENT RADIOTHERAPY, CISPLATIN, AND ETOPOSIDE [J].
HOSKINS, PJ ;
WONG, F ;
SWENERTON, KD ;
PIKE, JA ;
MANJI, M ;
MCMURTRIE, E ;
ACKER, B ;
LERICHE, J .
GYNECOLOGIC ONCOLOGY, 1995, 56 (02) :218-225
[10]   OAT-CELL CARCINOMA OF THE UTERINE CERVIX IN A PREGNANT WOMAN TREATED WITH CIS-DIAMMINEDICHLOROPLATINUM [J].
JACOBS, AJ ;
MARCHEVSKY, A ;
GORDON, RE ;
DEPPE, G ;
COHEN, CJ .
GYNECOLOGIC ONCOLOGY, 1980, 9 (03) :405-410